BModesto has received a marketing authorisation from the Dutch ‘College ter Beoordeling van Geneesmiddelen’ (CBG) for a new specialty medicinal product intended for use in specialist urological oncology hospital care, specifically for the treatment of non-muscle-invasive bladder cancer.
With this registration, BModesto further expands its Dutch specialty portfolio. The introduction aligns with the company’s strategic focus on contributing to the availability and continuity of medicines for specialist hospital treatments. Particularly in care areas such as oncology, security of supply remains an important focus.
“This approval marks an important step in the further development of our specialty portfolio in the Netherlands,” said Robin Marcus, Interim Commercial Director Europe. “Particularly with single-source medicines, we see how vulnerable availability can be. By strategically investing in the registration and introduction of specialist brands, we contribute to reducing shortages and ensuring continuity of care for patients within Dutch hospital care.”
Supply of the medicinal product is currently scheduled to commence in June 2026.
More general information about BModesto and its activities can be found at www.bmodesto.com
Detailed information regarding the specific medicinal products is exclusively available to qualified healthcare professionals.